DDInter1396 DDInter519
An oligosaccharide antibiotic produced by various streptomyces. [PubChem]
Dexlansoprazole is a new-generation proton pump inhibitor (PPI) used for the management of symptoms associated with gastroesophageal reflux disease (GERD) and erosive esophagitis. Dexlansoprazole is the R-enantiomer of , which is composed of a racemic mixture of the R- and S-enantiomers. Compared to the older generation of PPIs (which includes , , and ), dexlansoprazole has a unique pharmacokinetic profile due to its delayed-release and dual-delivery release system: This aims to address some limitations of the older-generation PPIs, such as short plasma half-life and the need for meal-associated dosing.[A19566, A19568, A178084, A174244] Dexlansoprazole inhibits the final step in gastric acid production by blocking the (H+, K+)-ATPase enzyme.
Paromomycin {u} (Compound) resembles {v} (Compound) Neomycin
Neomycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dexlansoprazole
Paromomycin {u} (Compound) resembles {v} (Compound) Kanamycin
Kanamycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dexlansoprazole
Paromomycin {u} (Compound) resembles {v} (Compound) Neomycin
Neomycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cisplatin
Cisplatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dexlansoprazole
Paromomycin {u} (Compound) resembles {v} (Compound) Tobramycin
Tobramycin {u} (Compound) resembles {v} (Compound) Kanamycin
Kanamycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dexlansoprazole
Paromomycin {u} (Compound) resembles {v} (Compound) Kanamycin
Kanamycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Acetylsalicylic acid
Acetylsalicylic acid {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dexlansoprazole
Paromomycin {u} (Compound) resembles {v} (Compound) Neomycin
Neomycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Plazomicin
Plazomicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dexlansoprazole
Paromomycin {u} (Compound) resembles {v} (Compound) Amikacin
Amikacin {u} (Compound) resembles {v} (Compound) Neomycin
Neomycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dexlansoprazole
Paromomycin {u} (Compound) resembles {v} (Compound) Kanamycin
Kanamycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Choline salicylate
Choline salicylate {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dexlansoprazole
Paromomycin {u} (Compound) resembles {v} (Compound) Neomycin
Neomycin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Digoxin
Digoxin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dexlansoprazole
Paromomycin {u} (Compound) resembles {v} (Compound) Neomycin
Neomycin {u} may lead to a major life threatening interaction when taken with {v} Etacrynic acid
Etacrynic acid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dexlansoprazole
Paromomycin (Compound) resembles Neomycin (Compound) and Neomycin may cause a moderate interaction that could exacerbate diseases when taken with Dexlansoprazole
Paromomycin (Compound) resembles Kanamycin (Compound) and Kanamycin may cause a moderate interaction that could exacerbate diseases when taken with Dexlansoprazole
Paromomycin (Compound) resembles Neomycin (Compound) and Neomycin may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin and Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Dexlansoprazole
Paromomycin (Compound) resembles Tobramycin (Compound) and Tobramycin (Compound) resembles Kanamycin (Compound) and Kanamycin may cause a moderate interaction that could exacerbate diseases when taken with Dexlansoprazole
Paromomycin (Compound) resembles Kanamycin (Compound) and Kanamycin may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a minor interaction that can limit clinical effects when taken with Dexlansoprazole
Paromomycin (Compound) resembles Neomycin (Compound) and Neomycin may cause a moderate interaction that could exacerbate diseases when taken with Plazomicin and Plazomicin may cause a moderate interaction that could exacerbate diseases when taken with Dexlansoprazole
Paromomycin (Compound) resembles Amikacin (Compound) and Amikacin (Compound) resembles Neomycin (Compound) and Neomycin may cause a moderate interaction that could exacerbate diseases when taken with Dexlansoprazole
Paromomycin (Compound) resembles Kanamycin (Compound) and Kanamycin may cause a moderate interaction that could exacerbate diseases when taken with Choline salicylate and Choline salicylate may cause a minor interaction that can limit clinical effects when taken with Dexlansoprazole
Paromomycin (Compound) resembles Neomycin (Compound) and Neomycin may cause a minor interaction that can limit clinical effects when taken with Digoxin and Digoxin may cause a moderate interaction that could exacerbate diseases when taken with Dexlansoprazole
Paromomycin (Compound) resembles Neomycin (Compound) and Neomycin may lead to a major life threatening interaction when taken with Etacrynic acid and Etacrynic acid may cause a moderate interaction that could exacerbate diseases when taken with Dexlansoprazole